medwireNews: Biomarkers could be useful for helping patients with subjective cognitive decline (SCD) better understand the pathology associated with their symptoms, but consensus suggests that more work is needed before they are tested in every patient.
26-03-2024 | Alzheimer's Disease | News
CONy 2024